JATT II Acquisition Corp Successfully Completes IPO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Newsfilter
- Successful IPO: JATT II Acquisition Corp completed its initial public offering on April 20, 2026, issuing 6,000,000 ordinary shares at $10.00 each, raising a total of $60 million, reflecting strong market confidence in its future prospects.
- Market Listing: The ordinary shares began trading on the Nasdaq Global Market (NASDAQ) under the ticker symbol 'JATT' on April 17, 2026, providing the company with enhanced market visibility and financing opportunities.
- Underwriter Selection: Guggenheim Securities, LLC acted as the sole book-running manager for the IPO and has been granted a 45-day option to purchase up to 900,000 additional ordinary shares at the IPO price to cover over-allotments, further enhancing market liquidity.
- Strategic Focus: JATT II Acquisition Corp intends to concentrate on healthcare and related sectors, particularly biotechnology and life sciences, aiming to leverage the management team's expertise and access to capital markets to drive potential business combinations and enhance competitiveness in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JATT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JATT
Wall Street analysts forecast JATT stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.986
Low
Averages
High
Current: 10.986
Low
Averages
High
No data
About JATT
JATT II Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target, and the Company has not engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. The Company is not engaged in any business operations and has not generated any revenue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JATT II Acquisition Corp Successfully Completes IPO
- Successful IPO: JATT II Acquisition Corp completed its initial public offering on April 20, 2026, issuing 6,000,000 ordinary shares at $10.00 each, raising a total of $60 million, reflecting strong market confidence in its future prospects.
- Market Listing: The ordinary shares began trading on the Nasdaq Global Market (NASDAQ) under the ticker symbol 'JATT' on April 17, 2026, providing the company with enhanced market visibility and financing opportunities.
- Underwriter Selection: Guggenheim Securities, LLC acted as the sole book-running manager for the IPO and has been granted a 45-day option to purchase up to 900,000 additional ordinary shares at the IPO price to cover over-allotments, further enhancing market liquidity.
- Strategic Focus: JATT II Acquisition Corp intends to concentrate on healthcare and related sectors, particularly biotechnology and life sciences, aiming to leverage the management team's expertise and access to capital markets to drive potential business combinations and enhance competitiveness in the industry.
See More
JATT II Acquisition Raises $60 Million for Biotech Focus
- Funding Details: JATT II Acquisition successfully raised $60 million by offering 6 million shares at $10 each, reflecting ongoing market interest in the biotech and life sciences sectors.
- Management Background: Led by CEO and Chairman Someit Sidhu, who has founded and managed several healthcare companies, including his recent role as CEO of Khanda Therapeutics, indicating strong industry expertise.
- Investment Focus: The SPAC plans to target healthcare and related businesses, with a primary emphasis on biotechnology and broader life sciences, aiming to capitalize on market growth potential.
- Transaction Arrangement: The company will trade on Nasdaq under the symbol JATT, with Guggenheim Securities acting as the sole bookrunner for the deal, ensuring professionalism and smooth execution of the transaction.
See More
JATT II Acquisition Corp Successfully Completes IPO
- Successful IPO: JATT II Acquisition Corp completed its initial public offering on April 20, 2026, issuing 6,000,000 ordinary shares at $10.00 each, raising a total of $60 million, reflecting strong market confidence in its future prospects.
- Market Listing: The ordinary shares began trading on the Nasdaq Global Market (NASDAQ) under the ticker symbol 'JATT' on April 17, 2026, providing the company with enhanced market visibility and financing opportunities.
- Underwriter Selection: Guggenheim Securities, LLC acted as the sole book-running manager for the IPO and has been granted a 45-day option to purchase up to 900,000 additional ordinary shares at the IPO price to cover over-allotments, further enhancing market liquidity.
- Strategic Focus: JATT II Acquisition Corp intends to concentrate on healthcare and related sectors, particularly biotechnology and life sciences, aiming to leverage the management team's expertise and access to capital markets to drive potential business combinations and enhance competitiveness in the industry.
See More
JATT II Acquisition Raises $60 Million for Biotech Focus
- Funding Details: JATT II Acquisition successfully raised $60 million by offering 6 million shares at $10 each, reflecting ongoing market interest in the biotech and life sciences sectors.
- Management Background: Led by CEO and Chairman Someit Sidhu, who has founded and managed several healthcare companies, including his recent role as CEO of Khanda Therapeutics, indicating strong industry expertise.
- Investment Focus: The SPAC plans to target healthcare and related businesses, with a primary emphasis on biotechnology and broader life sciences, aiming to capitalize on market growth potential.
- Transaction Arrangement: The company will trade on Nasdaq under the symbol JATT, with Guggenheim Securities acting as the sole bookrunner for the deal, ensuring professionalism and smooth execution of the transaction.
See More
